FAINTUCH, BLUMA L.SEO, DANIELEOLIVEIRA, ERICA A. deTARGINO, ROSELAINE C.MORO, ANA M.2017-08-142017-08-142017FAINTUCH, BLUMA L.; SEO, DANIELE; OLIVEIRA, ERICA A. de; TARGINO, ROSELAINE C.; MORO, ANA M. Evaluation of the influence of the conjugation site of the chelator agent HYNIC to GLP1 antagonist radiotracer for insulinoma diagnosis. <b>Current Radiopharmaceuticals</b>, v. 10, n. 1, p. 65-72, 2017. DOI: <a href="https://dx.doi.org/10.2174/1874471010666170126143636">10.2174/1874471010666170126143636</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/27705.1874-4729http://repositorio.ipen.br/handle/123456789/27705Background and Objective: Radiotracer diagnosis of insulinoma, can be done using somatostatin or glucagon-like peptide 1 (GLP-1). Performance of GLP-1 antagonists tends to be better than of agonists. Methods: We investigated the uptake of the antagonist exendin (9-39), radiolabeled with technetium-99m. Two different sites of the biomolecule were selected for chelator attachment. Results: HYNIC-beta Ala chelator attached to serine (C-terminus) of exendin, was associated with higher tumor uptake than to aspartate (N-terminus). Conclusion: The chelator position in the biomolecule influenced receptor uptake.65-72closedAccesstracer techniquesinsulinglucagonpeptide hormonestechnetium 99Artigo de periódico11010.2174/1874471010666170126143636Sem Percentil